For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
The COVID-19 global pandemic has had a significant impact on the conduct of pediatric and adult clinical drug trials. Many trials have halted enrollment, and there are multiple challenges with setting up remote visits, performing laboratory and other study assessments, and shipping study drug to patient homes. Furthermore, endpoint assessments for these trials have been substantially impacted. The following are several considerations for pediatric clinical drug trials:
The COVID-19 pandemic affects pediatric patients’ overall care in several ways, while impacting their participation in clinical trials. Although current data suggest that COVID-19 infection tends to be mild or even asymptomatic in pediatric patients, those who are younger or have significant underlying medical conditions are at higher risk for more severe illness. In addition, due to high rates of asymptomatic infections, children might be contributing to community transmission of COVID-19.
Depending on the anticipated duration of social distancing measures, additional innovative and virtual options will need to be considered by pediatric healthcare providers to maintain the overall quality of care. There may also need to be a shift in the clinical trial industry towards developing therapies which are easily self-administered by patients at home, as well as virtual tools to screen for chronic pediatric diseases.
This is an extraordinarily challenging time for pediatric healthcare providers, clinical researchers and the children themselves. Parexel has a full range of virtual solutions that can be incorporated into these trials whenever possible to help minimize the disruption.
For a more complete exploration of the implications of COVID-19 on Pediatric Clinical Trials, please read our article COVID-19 Risks for Pediatric Patients and Implications for Clinical Trials.
Master Protocols from Design to Delivery
Sep 30, 2021
What COVID Taught Us About Focus, Innovation, and Leadership
Sep 24, 2021
Reducing technology burdens: How sponsors and CROs can empower sites
Feb 7, 2024
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Part 1: Practically Speaking: Driving Clinical Transformation
Feb 9, 2022
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022
Master Protocol Trials: What Are the Elements of Success?
Dec 1, 2021
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Part 1: Risk-based Quality Management (RBQM) Video Series
Nov 11, 2021
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
End-to-end risk management: Getting the most from your program
Apr 4, 2022